Novo Nordisk's Summer Rally Builds on Buybacks, Production Push, and Two Pipeline Catalysts
Published on 07/01/2026 at 03:14 | Redaktion boerse-global.de
Novo Nordisk has strung together a double-digit monthly gain, reclaiming its 200-day moving average at 40.88 euros and closing Tuesday at 42.07 euros. The Danish drugmaker's shares have climbed roughly 11% in the past 30 days, lifted by a heavy buyback schedule, fresh manufacturing expansions in Europe and Asia, and the prospect of a second-half catalyst from its hemophilia pipeline.
The company's 15 billion Danish kroner repurchase programme continues to underpin the stock. Since February, Novo Nordisk has bought back 22 million of its own B-shares, including 1.05 million scooped up in late June, for a cumulative outlay of about 5.9 billion kroner. That effort has seen the company accumulate nearly 1% of its total share capital, providing steady demand during a period that has otherwise been volatile — the stock is still down roughly 6% year-to-date.
Operationally, management is racing to keep pace with surging demand for its GLP-1 therapies. In June, a new production facility in the Czech Republic came online, representing an investment of 3.5 billion kroner. The site will manufacture supporting proteins for the next generation of diabetes and obesity drugs. Separately, a partnership with India's Shantha Biologics, announced this week, shifts some filling and assembly work to Hyderabad, securing additional capacity just as the oral version of Wegovy won UK approval in June.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Investors have a near-term data event to digest in mid-July, when Novo Nordisk presents at the International Society on Thrombosis and Haemostasis congress in Paris. The company will unveil long-term results from the FRONTIER4 study of its haemophilia candidate Mim8, alongside data from the explorer10 trial evaluating Alhemo in children. Success in these trials could broaden Novo Nordisk's revenue base beyond the blockbuster weight-loss and diabetes franchise.
The next major checkpoint, however, is the second-quarter earnings report due on 5 August 2026. JPMorgan analyst Richard Vosser expects the company to raise its full-year guidance, citing the sustained boom in GLP-1 therapies and the successful launch of the oral Wegovy pill. His rating stays at Neutral with a price target of 250 Danish kroner. Jefferies' Michael Leuchten is more cautious, flagging second-half uncertainties, but retains a Hold and a target of 285 kroner.
Technically, the recent rally has pushed the relative strength index to 69, flirting with overbought territory — a factor behind Tuesday's slight dip of 0.66%. Still, with the stock now trading above both its 50-day and 200-day moving averages, the chart has turned constructive. The August report will test whether fundamental momentum can validate the technical breakout.
Ad
Novo Nordisk Stock: New Analysis - 1 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
